BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T110000
DTEND;TZID=America/Vancouver:20210602T120000
DTSTAMP:20210528T200943Z
CREATED:20210528T200943Z
LAST-MODIFIED:20210528T200943Z
UID:16703-1622631600-1622635200@scienceinvancouver.com
SUMMARY:The Centre for Blood Research Virtual Seminar Series: Dr. Eun-Ju Lee
DESCRIPTION:Eun-Ju Lee\nAssistant Professor\, Weill Cornell Medical College\, Department of Medicine\, Division of Hematology \n“SARS-CoV-2 Vaccination and Immune Thrombocytopenia”\nCases of severe thrombocytopenia following SARS-CoV-2 vaccination in patients without previous immune thrombocytopenia (ITP) including an early fatality raised concern\, particularly among those with preexisting ITP\, regarding the safety of vaccination. We reviewed the Vaccine Adverse Events Reporting System (VAERS) to identify cases suspicious for de novo ITP (last access March 19\, 2021) and gathered data across several centers regarding adult patients with ITP who received a SARS-CoV2 vaccine. Our (yet unpublished) findings support that the majority of patients with ITP did well after SARS-CoV-2 vaccination.
URL:https://scienceinvancouver.com/event/the-centre-for-blood-research-virtual-seminar-series-dr-eun-ju-lee/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T110000
DTEND;TZID=America/Vancouver:20210602T120000
DTSTAMP:20210528T200943Z
CREATED:20210528T200943Z
LAST-MODIFIED:20210528T200943Z
UID:26396-1622631600-1622635200@scienceinvancouver.com
SUMMARY:The Centre for Blood Research Virtual Seminar Series: Dr. Eun-Ju Lee
DESCRIPTION:Eun-Ju Lee\nAssistant Professor\, Weill Cornell Medical College\, Department of Medicine\, Division of Hematology \n“SARS-CoV-2 Vaccination and Immune Thrombocytopenia”\nCases of severe thrombocytopenia following SARS-CoV-2 vaccination in patients without previous immune thrombocytopenia (ITP) including an early fatality raised concern\, particularly among those with preexisting ITP\, regarding the safety of vaccination. We reviewed the Vaccine Adverse Events Reporting System (VAERS) to identify cases suspicious for de novo ITP (last access March 19\, 2021) and gathered data across several centers regarding adult patients with ITP who received a SARS-CoV2 vaccine. Our (yet unpublished) findings support that the majority of patients with ITP did well after SARS-CoV-2 vaccination.
URL:https://scienceinvancouver.com/event/the-centre-for-blood-research-virtual-seminar-series-dr-eun-ju-lee-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T110000
DTEND;TZID=America/Vancouver:20210602T120000
DTSTAMP:20210528T200943Z
CREATED:20210528T200943Z
LAST-MODIFIED:20210528T200943Z
UID:28011-1622631600-1622635200@scienceinvancouver.com
SUMMARY:The Centre for Blood Research Virtual Seminar Series: Dr. Eun-Ju Lee
DESCRIPTION:Eun-Ju Lee\nAssistant Professor\, Weill Cornell Medical College\, Department of Medicine\, Division of Hematology \n“SARS-CoV-2 Vaccination and Immune Thrombocytopenia”\nCases of severe thrombocytopenia following SARS-CoV-2 vaccination in patients without previous immune thrombocytopenia (ITP) including an early fatality raised concern\, particularly among those with preexisting ITP\, regarding the safety of vaccination. We reviewed the Vaccine Adverse Events Reporting System (VAERS) to identify cases suspicious for de novo ITP (last access March 19\, 2021) and gathered data across several centers regarding adult patients with ITP who received a SARS-CoV2 vaccine. Our (yet unpublished) findings support that the majority of patients with ITP did well after SARS-CoV-2 vaccination.
URL:https://scienceinvancouver.com/event/the-centre-for-blood-research-virtual-seminar-series-dr-eun-ju-lee-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T110000
DTEND;TZID=America/Vancouver:20210602T120000
DTSTAMP:20210528T200943Z
CREATED:20210528T200943Z
LAST-MODIFIED:20210528T200943Z
UID:31094-1622631600-1622635200@scienceinvancouver.com
SUMMARY:The Centre for Blood Research Virtual Seminar Series: Dr. Eun-Ju Lee
DESCRIPTION:Eun-Ju Lee\nAssistant Professor\, Weill Cornell Medical College\, Department of Medicine\, Division of Hematology \n“SARS-CoV-2 Vaccination and Immune Thrombocytopenia”\nCases of severe thrombocytopenia following SARS-CoV-2 vaccination in patients without previous immune thrombocytopenia (ITP) including an early fatality raised concern\, particularly among those with preexisting ITP\, regarding the safety of vaccination. We reviewed the Vaccine Adverse Events Reporting System (VAERS) to identify cases suspicious for de novo ITP (last access March 19\, 2021) and gathered data across several centers regarding adult patients with ITP who received a SARS-CoV2 vaccine. Our (yet unpublished) findings support that the majority of patients with ITP did well after SARS-CoV-2 vaccination.
URL:https://scienceinvancouver.com/event/the-centre-for-blood-research-virtual-seminar-series-dr-eun-ju-lee-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T110000
DTEND;TZID=America/Vancouver:20210602T120000
DTSTAMP:20210528T200943Z
CREATED:20210528T200943Z
LAST-MODIFIED:20210528T200943Z
UID:32554-1622631600-1622635200@scienceinvancouver.com
SUMMARY:The Centre for Blood Research Virtual Seminar Series: Dr. Eun-Ju Lee
DESCRIPTION:Eun-Ju Lee\nAssistant Professor\, Weill Cornell Medical College\, Department of Medicine\, Division of Hematology \n“SARS-CoV-2 Vaccination and Immune Thrombocytopenia”\nCases of severe thrombocytopenia following SARS-CoV-2 vaccination in patients without previous immune thrombocytopenia (ITP) including an early fatality raised concern\, particularly among those with preexisting ITP\, regarding the safety of vaccination. We reviewed the Vaccine Adverse Events Reporting System (VAERS) to identify cases suspicious for de novo ITP (last access March 19\, 2021) and gathered data across several centers regarding adult patients with ITP who received a SARS-CoV2 vaccine. Our (yet unpublished) findings support that the majority of patients with ITP did well after SARS-CoV-2 vaccination.
URL:https://scienceinvancouver.com/event/the-centre-for-blood-research-virtual-seminar-series-dr-eun-ju-lee-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T120000
DTEND;TZID=America/Vancouver:20210602T130000
DTSTAMP:20210510T155817Z
CREATED:20210510T155652Z
LAST-MODIFIED:20210510T155817Z
UID:16459-1622635200-1622638800@scienceinvancouver.com
SUMMARY:WiP Seminar: Dr. Nathaniel Hawkins
DESCRIPTION:Nathaniel Hawkins\, MBChB\, MD\, MPH\nScientist\, CHÉOS\nClinical Assistant Professor\, Division of Cardiology\, UBC \nClick here to register (required) \nUse of implantable cardioverter defibrillators following out-of-hospital cardiac arrest: a linked analysis of prospective registries in British Columbia \nIn randomized controlled trials of secondary prevention of sudden cardiac death\, implantable cardioverter defibrillators (ICDs) reduced the risk of all-cause and arrhythmic death. These studies enrolled patients with documented ventricular tachycardia (VT) or ventricular fibrillation (VF) and excluded those with reversible causes. Approximately half of patients with VF/VT out of hospital cardiac arrest surviving to discharge have reversible causes. Prior studies have suggested appropriate use of secondary prevention ICDs has been surprisingly low (7% to 34%)\, although these studies were conducted in the 1990s and early millennium\, and none excluded patients with reversible causes. We therefore examined the rate\, predictors and associated outcomes of ICD implant following OHCA in patients with shockable presenting rhythm and no reversible cause.
URL:https://scienceinvancouver.com/event/wip-seminar-dr-nathaniel-hawkins/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T120000
DTEND;TZID=America/Vancouver:20210602T130000
DTSTAMP:20210510T155652Z
CREATED:20210510T155652Z
LAST-MODIFIED:20210510T155652Z
UID:26383-1622635200-1622638800@scienceinvancouver.com
SUMMARY:WiP Seminar: Dr. Nathaniel Hawkins
DESCRIPTION:Nathaniel Hawkins\, MBChB\, MD\, MPH\nScientist\, CHÉOS\nClinical Assistant Professor\, Division of Cardiology\, UBC \nClick here to register (required) \nUse of implantable cardioverter defibrillators following out-of-hospital cardiac arrest: a linked analysis of prospective registries in British Columbia \nIn randomized controlled trials of secondary prevention of sudden cardiac death\, implantable cardioverter defibrillators (ICDs) reduced the risk of all-cause and arrhythmic death. These studies enrolled patients with documented ventricular tachycardia (VT) or ventricular fibrillation (VF) and excluded those with reversible causes. Approximately half of patients with VF/VT out of hospital cardiac arrest surviving to discharge have reversible causes. Prior studies have suggested appropriate use of secondary prevention ICDs has been surprisingly low (7% to 34%)\, although these studies were conducted in the 1990s and early millennium\, and none excluded patients with reversible causes. We therefore examined the rate\, predictors and associated outcomes of ICD implant following OHCA in patients with shockable presenting rhythm and no reversible cause.
URL:https://scienceinvancouver.com/event/wip-seminar-dr-nathaniel-hawkins-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T120000
DTEND;TZID=America/Vancouver:20210602T130000
DTSTAMP:20210510T155652Z
CREATED:20210510T155652Z
LAST-MODIFIED:20210510T155652Z
UID:27998-1622635200-1622638800@scienceinvancouver.com
SUMMARY:WiP Seminar: Dr. Nathaniel Hawkins
DESCRIPTION:Nathaniel Hawkins\, MBChB\, MD\, MPH\nScientist\, CHÉOS\nClinical Assistant Professor\, Division of Cardiology\, UBC \nClick here to register (required) \nUse of implantable cardioverter defibrillators following out-of-hospital cardiac arrest: a linked analysis of prospective registries in British Columbia \nIn randomized controlled trials of secondary prevention of sudden cardiac death\, implantable cardioverter defibrillators (ICDs) reduced the risk of all-cause and arrhythmic death. These studies enrolled patients with documented ventricular tachycardia (VT) or ventricular fibrillation (VF) and excluded those with reversible causes. Approximately half of patients with VF/VT out of hospital cardiac arrest surviving to discharge have reversible causes. Prior studies have suggested appropriate use of secondary prevention ICDs has been surprisingly low (7% to 34%)\, although these studies were conducted in the 1990s and early millennium\, and none excluded patients with reversible causes. We therefore examined the rate\, predictors and associated outcomes of ICD implant following OHCA in patients with shockable presenting rhythm and no reversible cause.
URL:https://scienceinvancouver.com/event/wip-seminar-dr-nathaniel-hawkins-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T120000
DTEND;TZID=America/Vancouver:20210602T130000
DTSTAMP:20210510T155652Z
CREATED:20210510T155652Z
LAST-MODIFIED:20210510T155652Z
UID:31081-1622635200-1622638800@scienceinvancouver.com
SUMMARY:WiP Seminar: Dr. Nathaniel Hawkins
DESCRIPTION:Nathaniel Hawkins\, MBChB\, MD\, MPH\nScientist\, CHÉOS\nClinical Assistant Professor\, Division of Cardiology\, UBC \nClick here to register (required) \nUse of implantable cardioverter defibrillators following out-of-hospital cardiac arrest: a linked analysis of prospective registries in British Columbia \nIn randomized controlled trials of secondary prevention of sudden cardiac death\, implantable cardioverter defibrillators (ICDs) reduced the risk of all-cause and arrhythmic death. These studies enrolled patients with documented ventricular tachycardia (VT) or ventricular fibrillation (VF) and excluded those with reversible causes. Approximately half of patients with VF/VT out of hospital cardiac arrest surviving to discharge have reversible causes. Prior studies have suggested appropriate use of secondary prevention ICDs has been surprisingly low (7% to 34%)\, although these studies were conducted in the 1990s and early millennium\, and none excluded patients with reversible causes. We therefore examined the rate\, predictors and associated outcomes of ICD implant following OHCA in patients with shockable presenting rhythm and no reversible cause.
URL:https://scienceinvancouver.com/event/wip-seminar-dr-nathaniel-hawkins-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210602T120000
DTEND;TZID=America/Vancouver:20210602T130000
DTSTAMP:20210510T155652Z
CREATED:20210510T155652Z
LAST-MODIFIED:20210510T155652Z
UID:32541-1622635200-1622638800@scienceinvancouver.com
SUMMARY:WiP Seminar: Dr. Nathaniel Hawkins
DESCRIPTION:Nathaniel Hawkins\, MBChB\, MD\, MPH\nScientist\, CHÉOS\nClinical Assistant Professor\, Division of Cardiology\, UBC \nClick here to register (required) \nUse of implantable cardioverter defibrillators following out-of-hospital cardiac arrest: a linked analysis of prospective registries in British Columbia \nIn randomized controlled trials of secondary prevention of sudden cardiac death\, implantable cardioverter defibrillators (ICDs) reduced the risk of all-cause and arrhythmic death. These studies enrolled patients with documented ventricular tachycardia (VT) or ventricular fibrillation (VF) and excluded those with reversible causes. Approximately half of patients with VF/VT out of hospital cardiac arrest surviving to discharge have reversible causes. Prior studies have suggested appropriate use of secondary prevention ICDs has been surprisingly low (7% to 34%)\, although these studies were conducted in the 1990s and early millennium\, and none excluded patients with reversible causes. We therefore examined the rate\, predictors and associated outcomes of ICD implant following OHCA in patients with shockable presenting rhythm and no reversible cause.
URL:https://scienceinvancouver.com/event/wip-seminar-dr-nathaniel-hawkins-5/
LOCATION:Online
END:VEVENT
END:VCALENDAR